Irinotecan Cell Pharm

Irinotecan, the active ingredient in Irinotecan Cell Pharm, is a topoisomerase I inhibitor presented as an intravenous solution for intravenous use. It is employed in the treatment of metastatic colorectal cancer, as adjuvant therapy for colorectal cancer, and in other solid tumours as determined by clinical judgment.

GNH USA supplies Irinotecan Cell Pharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan is indicated for colorectal cancer and related solid tumours, acting on the topoisomerase I pathway.

- Metastatic colorectal cancer: improves overall survival when used in combination chemotherapy regimens. - Adjuvant treatment of colorectal cancer: reduces risk of disease recurrence after surgical resection. - Other solid tumours (clinical judgment): may be incorporated into protocols for selected gastrointestinal or pancreatic cancers.

Irinotecan may cause a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Neutropenia: reduced white‑blood‑cell count increasing infection risk. - Diarrhoea: often delayed and may be severe. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Alopecia: temporary hair loss. - Fatigue: generalized tiredness during treatment. - Abdominal cramping: related to gastrointestinal irritation.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent care. - Severe diarrhoea (colitis): can lead to dehydration and electrolyte imbalance. - Cholinergic syndrome: sweating, lacrimation, bradycardia, and bronchospasm. - Hypersensitivity reactions: rash, urticaria, or anaphylaxis. - Hepatic dysfunction: elevated transaminases or bilirubin. - Severe electrolyte disturbances: especially hypokalemia and hypomagnesemia.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor for toxicity. - Monitor blood counts: perform regular complete blood counts to detect neutropenia. - Assess liver function: evaluate hepatic enzymes and bilirubin prior to each cycle. - Evaluate gastrointestinal status: avoid use in patients with active bowel obstruction. - Pregnancy risk: contraindicated in pregnancy (Category D) due to fetal toxicity. - Dose adjustment: consider reduced dosing in patients with moderate hepatic impairment. - Store at ambient temperature: keep in original container, protect from light and moisture.

Irinotecan interacts with several drug classes that can alter its metabolism or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): raise SN‑38 levels and risk of severe neutropenia. - UGT1A1 inhibitors (e.g., atazanavir, indinavir): impair SN‑38 glucuronidation, increasing toxicity. - Concurrent myelosuppressive agents: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): enhanced bleeding risk due to mucosal injury. - Antidiarrhoeal agents (e.g., loperamide): may mask early signs of severe diarrhoea. - Electrolyte‑altering drugs (e.g., diuretics): monitor for hypokalaemia and hypomagnesaemia.